NCT04653480

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 61 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in second-line RAS/BRAF mutant and MSS colorectal cancer

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Surufatinib	250mg per oral, once daily
DRUG	Toripalimab	3mg/kg IV, once every 2 weeks
DRUG	chemotherapy	oxaliplatin or irinotecan based regimens, according to the first line treatment

Timeline

• Start date: 2021-02-01
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2020-12-04
• Last updated: 2023-07-17

Locations

1 site across 1 country: China